CompletedPhase 3NCT02008721

Progression Rate of MSA Under EGCG Supplementation as Anti-Aggregation-Approach

Studying Multiple system atrophy

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Dr. Johannes Levin
Principal Investigator: Johannes Levin, MD
Ludwig Maximilians University, Department of Neurology
Intervention: EGCG as putative neuroprotective agent(drug)
Enrollment: 92 target
Eligibility: 18 years · All sexes
Timeline: 2014 – 2016

Study locations (12)

Neurology Department, Ludwig-Maximilians University, München, Bavaria, Germany
Department of Neurology, Klinikum rechts der Isar, Technische Universität München, München, Bavaria, Germany
Kliniken Beelitz GmbH, Neurologisches Fachkrankenhaus für Bewegungsstörungen, Beelitz-Heilstätten, Germany
Charité - Universitätsmedizin Berlin, Berlin, Germany
Technische Universität Dresden, Dresden, Germany
Heinrich-Heine-Universität, Neurologische Klinik, Düsseldorf, Germany
Paracelsus-Elena-Klinik Kassel, Kassel, Germany
Universität Leipzig, Leipzig, Germany
Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Lübeck, Germany
Philipps Universität Marburg, Marburg, Germany
Eberhard Karls Universität Tübingen, Tübingen, Germany
Universitätsklinikum Ulm, Ulm, Germany

Collaborators

German Center for Neurodegenerative Diseases (DZNE) · Deutsche Parkinson Vereinigung · German Foundation for Neurology · ParkinsonFonds Deutschland gGmbH

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02008721 on ClinicalTrials.gov

Other trials for Multiple system atrophy

Additional recruiting or active studies for the same condition.

See all trials for Multiple system atrophy →

← Back to all trials